Titus Gylvin MD, PhD

General Manager

Roche Oy

www.roche.com

Roche is the world’s largest

biotech company

Roche’s combined strenghts in pharmaceuticals and diagnostics

have made it the leader in personalized healthcare.

Roche has brought 14 biopharmaceuticals to the market

and majority of its new molecules in development are based on

biotechnology.

Roche in Finland Roche has operated in Finland since 1982 Local decision making power due to decentralized global organization model Employees 90 Roche Oy 75 Roche Diagnostics Oy Ca. 30 clinical trials in Finland (01/2016)

Focus areas of Roche

Oncology

Rheumatology

Neuroscience

Respiratory

Immunology and infections

Ophthalmology

www.roche.com

A pioneer in cancer treatment

We have developed medicines for breast cancer, skin cancer,

colorectal cancer, ovarian cancer, lung cancer and to many

other cancers.

Out of all new Roche molecules in development about half are

studied for cancer treatments.

We are studying more than 20 investigational cancer

immunotherapy medicines, nine of which are in clinical trials.

Roche invests to research and

development more than any other

pharmaceutical company

FI/ROCH/1601/0007

Roche annual investment to R&D

is four times the spending on

prescription medicines in Finland

Roche annual report 2015

Currency exhange 31.12.2015

Roche R&D investment in 2015

8,6* Billion euros (globally)

Spending on

prescription

medicines in Finland

(IMS)

2,0 Billion euros

Roche has strong pipeline

In the next three years launches for up

to eight new medicines planned

Situation 28.1.2016 Roche reporting centre, Full year 2015 presentation,

www.roche.com Roche annual report 2015

New molecular

entities

New

indications

70 63 Phase I-IIIb Phase I-IIIb

Top 3 in BCG research surveys 2008- 2014

190 partnerships

currently managed around

the world

33 % of our research

pipeline comes from partnered

products

35 % of total

pharmaceutical sales from partnered

and in-licensed products (CHF 12 bn

in 2014)

61 Total new agreements

in 2015

4 acquistions

4 product transactions

45 R&D collaborations

2014-2015

10,7 billion euros on acquistions

Basel

New York

Boston San Francisco

Shanghai Tokyo

Academic collaboration around the world

Harvard

MIT

Karolinska Insititute

Universities in Basel

Zürich

Hebrew University

50

universities

Roche partnerships in Finland

Helsinki University & HUS

TAYS & FinnMedi

Auria Biobank

When evaluating partnership prospects we consider

Cultural fit

Opportunity of the new technology

Focus on our main disease areas

Potential to revolutionise the standard of care

Potential to be first in class or best in class

How to find us

http://www.roche.com/partnering/get_in_touch_with_us/partnering_contact_us.htm

FI/ROCH/1601/000

7